(RXL)

With a new year comes the opportunity to make changes, and that's what ProShares has done by swapping benchmarks on 23 ETFs, largely focused on their inverse and leveraged strategies.

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...

The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets...

The issuers were among a number of firms making changes to expense ratios and enacting splits.